Related Experiment Video

Updated: Dec 11, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.4K

[Pharmacology and Clinical Evaluation of Ensartinib Hydrochloride Capsule]

Yang Wang1, Xiaobin Yuan1, Jiayan Xiong1

  • 1Betta Pharmaceuticals Co., Ltd, Hangzhou 311100, China.

Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|August 26, 2020
PubMed

Insights

Ensartinib, a next-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), shows promise for treating ALK-positive non-small cell lung cancer (NSCLC). Clinical trials indicate its potential efficacy and safety in patients, including those with brain metastases.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality worldwide, with anaplastic lymphoma kinase (ALK) rearrangements occurring in approximately 5% of patients.
  • ALK-positive NSCLC patients often have a poor prognosis, necessitating urgent and effective treatment options.
  • Crizotinib resistance is a clinical challenge, highlighting the need for novel therapeutic agents.

Purpose of the Study:

  • To review the clinical trial data of ensartinib (X-396), a next-generation ALK tyrosine kinase inhibitor (TKI).
  • To discuss the preliminary efficacy, safety, pharmacology, and pharmacokinetics/pharmacodynamics of ensartinib in NSCLC patients.
  • To evaluate ensartinib's potential as a treatment for ALK-positive NSCLC, particularly in cases of crizotinib resistance and brain metastases.

Main Methods:

  • Review of data from Phase I to III clinical trials involving ensartinib.
  • Inclusion of data from both healthy volunteers and NSCLC patients.
  • Analysis of efficacy, safety, pharmacology, and pharmacokinetic/pharmacodynamic profiles.

Main Results:

  • Ensartinib demonstrates potent inhibition of ALK activity.
  • The drug shows effectiveness in controlling brain metastases, a common complication in NSCLC.
  • Preliminary data suggest a favorable safety profile and pharmacokinetic/pharmacodynamic characteristics.

Conclusions:

  • Ensartinib represents a promising next-generation ALK-TKI for ALK-positive NSCLC.
  • Its efficacy against brain metastases and potential to overcome crizotinib resistance warrant further investigation.
  • Ensartinib's comprehensive profile supports its role in the treatment landscape for advanced NSCLC.
Keywords:
Anaplastic lymphoma kinase tyrosine kinase inhibitorClinical studiesEnsartinibLung noplasms

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.0K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.4K

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
352
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.0K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
315
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
157
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.0K